The specialist cancer drug discovery and development business has released its AGM statement, recapping on a transformational year, and looking ahead to 2018. The key event of the last financial year was the licensing agreement with Sierra Oncology over Sareum’s Chk1 program. This has already significantly improved Sareum’s P&L and balance sheet with FYJun17 seeing payments of nearly £2m relating to the agreement, and Sareum recognising a maiden profit of £400k.
....14 Dec 2017
Lots to look forward to in 2018
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Lots to look forward to in 2018
Sareum Holdings plc (SAR:LON) | 20.5 0.8 24.2% | Mkt Cap: 20.2m
- Published:
14 Dec 2017 -
Author:
Derren Nathan -
Pages:
6
The specialist cancer drug discovery and development business has released its AGM statement, recapping on a transformational year, and looking ahead to 2018. The key event of the last financial year was the licensing agreement with Sierra Oncology over Sareum’s Chk1 program. This has already significantly improved Sareum’s P&L and balance sheet with FYJun17 seeing payments of nearly £2m relating to the agreement, and Sareum recognising a maiden profit of £400k.
....